TCGA-EW-A6SB-01A-12R-A32P-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 25
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.620
- ALLOGRAFT_REJECTION+0.600
- INTERFERON_GAMMA_RESPONSE+0.470
- MYC_TARGETS_V1+0.450
- INTERFERON_ALPHA_RESPONSE+0.440
- IL6_JAK_STAT3_SIGNALING+0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.330
- E2F_TARGETS+0.320
- INFLAMMATORY_RESPONSE+0.310
- WNT_BETA_CATENIN_SIGNALING+0.250
Top 10 suppressed
- PROTEIN_SECRETION-0.450
- TGF_BETA_SIGNALING-0.440
- UV_RESPONSE_DN-0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.390
- HEDGEHOG_SIGNALING-0.390
- ANGIOGENESIS-0.380
- ESTROGEN_RESPONSE_EARLY-0.360
- MITOTIC_SPINDLE-0.360
- HYPOXIA-0.200
- ANDROGEN_RESPONSE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AC-A6IW-01A-12R-A33J-07 | — | E | 0.945 |
| 2 | TCGA-B6-A0I2-01A-11R-A034-07 | — | E | 0.906 |
| 3 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.883 |
| 4 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.882 |
| 5 | TCGA-OL-A5D7-01A-11R-A27Q-07 | — | E | 0.870 |
| 6 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.864 |
| 7 | 20030081.TNBC | — | D | 0.860 |
| 8 | TCGA-D8-A1XL-01A-11R-A14M-07 | — | B | 0.854 |
| 9 | SRR8518297 | — | E | 0.851 |
| 10 | TCGA-A2-A3Y0-01A-11R-A239-07 | — | E | 0.851 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.620 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.600 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.470 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.250 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.160 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.140 | Idelalisib | — uncovered |